ABSI

Absci Corporation

Fundamental data last updated:July 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/11/2026

Business Summary

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

 


Analyze ABSI on TradingView

VALUATION

P/E

-7.85

Market Cap ($M USD)

$947.90M

Forward P/E

-67.56

PEG

-0.76

PRICE TO SALES

516.29

PRICE TO BOOK

5.41

EV / EBITDA

-8.17

5-Year Average P/E

Free Cash Flow Yield

-10.39%

DCF Value

$0.04

Graham Number

N/A

Price to FCF

-9.62

EV to FCF

-9.58

Earnings Yield

-12.73%

FCF Yield

-10.39%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.77

Next Year EPS Growth Estimate

-$0.09

Next Year Revenue Growth Estimate

$7.08B

Return on Equity (ROE)

-63.58%

FREE CASH FLOW

Operating Margin

-7000.82%

Debt-to-Equity

0.03

Piotroski F-Score

4

Altman Z-Score

17.95

Return on Invested Capital (ROIC)

-73.21%

Current Ratio

6.59

Quick Ratio

6.59

Net Debt to EBITDA

0.04

Interest Coverage

-1147.63

Gross Profit margin

-1,316.88%

FCF PER SHARE

$-0.64

REVENUE PER SHARE

$0.01

Analyze ABSI on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be pricing Absci Corporation with a level of optimism that defies its fundamentals. With a Forward P/E of 84.29, the stock is priced for perfection, yet its DCF Value is a mere fraction of its snapshot price, suggesting a significant overvaluation. The Altman Z-score of 17.22 indicates financial stability, but the negative Earnings Yield of -13.12% raises red flags about profitability. Despite a “Buy” consensus, the company’s financial health is questionable, with a negative ROIC of -73.21% reflecting poor capital efficiency.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Absci Corporation is well-positioned to leverage AI advancements for drug discovery and development. The industry's inherent focus on innovation aligns with modern tech shifts, potentially enhancing R&D efficiency. However, execution will be key to translating this potential into tangible results.

The Bull Case

For the optimistic investor, Absci's low Debt/Equity ratio of 0.03 and robust Current Ratio of 6.59 suggest a solid liquidity position. The Forward PEG ratio of 0.77 indicates potential undervaluation relative to growth, offering a glimmer of hope for future profitability. Despite a low Piotroski F-Score of 3, the company's ability to maintain a high Altman Z-score suggests resilience. These factors could appeal to those betting on a turnaround story in a high-growth industry.

The Bear Case

Absci's structural weaknesses are glaring. A Price/Sales ratio of 501.00 and Price/Book of 5.25 highlight an overextended valuation, while the negative Operating Margin of -7000.82% underscores severe operational inefficiencies. The stock's proximity to its 52-week high suggests technical overextension, and with a Gross Profit Margin of -13.17%, the company struggles to generate profit from its core operations. These metrics paint a picture of a company with significant execution risks.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$7.03

Institutional Ownership %

1-Year Beta

2.38

Insider Buying % (6 Mo)

Distance to 52-Week High

10.53%

Distance to 52-Week Low

63.16%

EARNINGS SURPRISE %

5.00%

50-DAY SMA

$4.15

200-DAY SMA

$3.40

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.